| Literature DB >> 28498330 |
Zoltán Kiss1, Nóra Judit Béres2, Erna Sziksz3,4, Bálint Tél5, Katalin Borka6, András Arató7, Attila J Szabó8,9, Gábor Veres10.
Abstract
Eosinophilic colitis (EC) is a common cause of haematochezia in infants and young children. The exact pathomechanism is not understood, and the diagnosis is challenging. The role of microRNAs as key class of regulators of mRNA expression and translation in patients with EC has not been explored. Therefore, the aim of the present study was to explore the miRNA profile in EC with respect to eosinophilic inflammation. Patients enrolled in the study (n = 10) had persistent rectal bleeding, and did not respond to elimination dietary treatment. High-throughput microRNA sequencing was carried out on colonic biopsy specimens of children with EC (EC: n = 4) and controls (C: n = 4) as a preliminary screening of the miRNA profile. Based on the next-generation sequencing (NGS) results and literature data, a potentially relevant panel of miRNAs were selected for further measurements by real-time reverse transcription (RT)-PCR (EC: n = 14, C: n = 10). Validation by RT-PCR resulted in significantly altered expression of miR-21, -31, -99b, -125a, -146a, -184, -221, -223, and -559 compared to controls (p ≤ 0.05). Elevation in miR-21, -99b, -146a, -221, and -223 showed statistically significant correlation to the extent of tissue eosinophilia. Based on our results, we conclude that the dysregulated miRNAs have a potential role in the regulation of apoptosis by targeting Protein kinase B/Mechanistic target of rapamycin (AKT/mTOR)-related pathways in inflammation by modulating Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-related signalling and eosinophil cell recruitment and activation, mainly by regulating the expression of the chemoattractant eotaxin and the adhesion molecule CD44. Our results could serve as a basis for further extended research exploring the pathomechanism of EC.Entities:
Keywords: eosinophilic colitis; haematochezia; microRNA
Mesh:
Substances:
Year: 2017 PMID: 28498330 PMCID: PMC5454962 DOI: 10.3390/ijms18051050
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Patient selection chart. EC: eosinophilic colitis.
Figure 2Expression of selected miRs in the colonic mucosa of children with eosinophilic colitis (EC) and controls (C). MiRs were selected based on the results of next-generation sequencing (NGS), and their colonic expression was validated by real-time reverse transcription polymerase chain reaction (RT-PCR). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. C.
Figure 3Correlation of miR-21, -99b, -146a, -221, and -223 with the extent of tissue eosinophilia in the colonic mucosa of paediatric patients with eosinophilic colitis. Class I: 0–10 eosinophil/high power field (eo/HPF), Class. II: 10–20 eo/HPF, Class III: 20–40 eo/HPF, Class IV: >40 eo/HPF, area of HPF = 0.2 mm2. Solid lines represent a regression line with dotted lines depicting 95% CI.
Figure 4Composite summary graph of the potential target points of the miRs correlated with tissue eosinophil level. Abbreviations: inhibitor of kappa B kinase (IKK), interleukin 1, 6, 8, 13 (IL-1, -6, -8, -13), interleukin receptor-1R, -33R, 18R (IL-1R, -33R, -18R), interleukin-1 receptor-associated kinase 1 (IRAK1), mammalian target of rapamycin complex (mTORc), microRNA-21, -31, -99b, -146a, -184, -221, -223 (miR-21, -31, -99b, -146a, -184, -221, -223), myeloid differentiation primary response 88 (MyD88), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor (IκB), phosphatase and tensin homolog (PTEN), phosphatidylinositol (3,4,5)-trisphosphate (PIP3), phosphatidylinositol 4,5-bisphosphate (PIP2), phosphatidylinositol-3-kinase (PI3K), phosphoinositide dependent protein kinase (PDK), programmed cell death protein 4 (PDCD4), protein kinase B (Akt), receptor activator of nuclear factor kappa-B ligand (RANKL), TNF receptor associated factor-6 (TRAF6), Toll-like receptor-1-2, 4-6 (TLR 1-2, 4-6), tumor necrosis factor alpha (TNFα), tumor necrosis factor, α-induced protein 3 (A20).
Clinical characteristics and laboratory parameters of patients enrolled in the study (A) in the next-generation sequencing groups; and (B) in the real-time reverse transcription polymerase chain reaction validation groups. BMI: body mass index, CRP: C-reactive protein; Data are presented as mean ± SD * p ≤ 0.05 vs. Control, *** p ≤ 0.0001 vs. Control.
| 4 | 4 | |
| Male/Female | 2/2 | 3/1 |
| Age (months) | 136.5 ± 35.78 | 8.88 ± 5.14 * |
| BMI (kg/m2) | - | 18.66 ± 3.79 |
| Iron (µmol/L) | 10.75 ± 2.5 | 13.25 ± 3.57 |
| Albumin (g/L) | 51.75 ± 8.81 | - |
| Haemoglobin (g/L) | 134.3 ± 7.76 | 121.8 ± 3.64 |
| Haematocrit (%) | 0.39 ± 0.02 | 0.34 ± 0.013 |
| Platelet count (Giga/L) | 325.8 ± 21.10 | 440.5 ± 57.81 |
| CRP (mg/L) | 1.25 ± 1.4 | 0 |
| 14 | 10 | |
| Male/Female | 6/8 | 8/2 |
| Age (months) | 29.82 ± 17.08 | 5.7 ± 4.76 *** |
| BMI (kg/m2) | 16.15 ± 1.6 | 16.21 ± 1.74 |
| Length-weight percentile (%) | - | 42.25 ± 34.92 |
| Iron (µmol/L) | 15.70 ± 4.9 | 9.89 ± 5.62 * |
| Albumin (g/L) | 45.8 ± 2.01 | 44 ± 4.24 |
| Haemoglobin (g/L) | 122.1 ± 12.26 | 112.6 ± 8.32 * |
| Haematocrit (%) | 35.18 ± 2.8 | 32 ± 1.94 |
| Platelet count (Giga/L) | 364.6 ± 87.09 | 394.5 ± 104.1 |
| CRP (mg/L) | 0.79 ± 1.4 | 3.44 ± 8.49 |
Figure 5Reference of the histologic assessment. Detection of eosinophil cells with Hematoxylin and Eosin (H&E) staining: 3–4/HPF eosinophil cells were detectable in normal biopsy (A, B). In a patient with eosinophil colitis, 100–120 eosinophils per HPF are seen (C, D).